Keyphrases
Metabolic
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
R-CHOP
100%
Complete Response
100%
Positron Emission tomography-CT
100%
Interim Positron Emission Tomography
100%
Response Group
60%
Overall Survival
30%
Progression-free Survival
30%
Chemotherapy
20%
Nave
20%
Lymphoma Patients
20%
Positive Groups
20%
Positron Emission Tomography
10%
Response to Treatment
10%
Adaptive Therapy
10%
Malignant Lymphoma
10%
Survival Outcomes
10%
R-CHOP Chemotherapy
10%
Response Monitoring
10%
Risk Adaptive
10%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Chemotherapy
75%
Overall Survival
75%
Progression Free Survival
75%
Lymphoma
25%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Positron Emission Tomography
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Chemotherapy
27%
Overall Survival
27%
Progression Free Survival
27%
Lymphoma
9%
Immunology and Microbiology
B Cell
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Positron Emission Tomography
100%
Overall Survival
27%
Progression Free Survival
27%
Veterinary Science and Veterinary Medicine